Efficacy and safety of high dose (≥ 8 mg/kg/day) daptomycin;Eficacia y seguridad de daptomicina en dosis elevadas (≥ 8 mg/kg/día)

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 29, Issue 6, 2011, Pages 425-427

  Parra Ruiz, Jorge ^a   Peña Monje, Alejandro ^a   Tomás Jiménez, Cristina ^a,b   Pomares Mora, José ^a   Hernández Quero, José ^a  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Efficacy; High dose daptomycin; Safety

Indexed keywords

CREATINE KINASE; DAPTOMYCIN;

ARTICLE; CLINICAL FEATURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MYOPATHY; SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 79959326421     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2011.02.012     Document Type: Article

References (9)

1. Hobbs JK, Miller K, O'Neill AJ, Chopra I. Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus. J Antimicrob Chemoth. 2008;62:1003-8.
2. Pigrau C, Almirante B. Oxazolidinones, glycopeptides and cyclic lipopeptides. Enferm Infecc Microbiol Clin. 2009;27:236-46.
3. Figueroa DA, Mangini E, Amodio-Groton M, Vardianos B, Melchert A, Fana C. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis. 2009;49:177-80.
4. Katz DE, Lindfield KC, Steenbergen JN, Benziger DP, Blackerby KJ, Knapp AG, et al. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int J Clin Pract. 2008;62:1455-64.
5. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis. 2010;50:1568-74.
6. Tobin CM, Darville JM, Lovering AM,Macgowan AP. An HPLC assay for daptomycin in serum. J Antimicrob Chemother. 2008;62:1462-3.
7. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Ch. 2006;50:3245-9.
8. Noakes TD, Kotzenberg G, McArthur PS, Dykman J. Elevated serum creatine kinase MB and creatine kinase BB-isoenzyme fractions after ultra-marathon running. Eur J Appl Physiol Occup Physiol. 1983;52:75-9. (Pubitemid 14245203)
9. Odero RO, Cleveland KO, Gelfand MS. Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor. J Antimicrob Chemother. 2009;63:1299-300.